Tempus AI

Ark Investment sold 57,819 Tempus AI shares (≈$4 million) as the healthcare AI stock surged following positive trial updates tied to Merck and Moderna. Tempus has climbed roughly 38% since Aug. 18 and is now Ark Innovation ETF's second-largest holding, after strong quarterly revenue and raised guidance. The sale is presented as profit-taking amid broader Ark portfolio rebalancing rather than a shift in conviction on AI-driven healthcare. » Altro su finance.yahoo.com

Tempus AI reported its first net profit in Q2 2026 of $5.6 million, with revenue rising 22% to $382.5 million. Due to strong demand in oncology, management raised the annual guidance to as much as $1.605 billion. The company continues to partner with major pharma firms like AstraZeneca and remains focused on AI-powered diagnostics. » Altro su finanzen.net

Andrew Polovin, Tempus AI's EVP and chief legal officer, sold 30,075 shares for about $1.5 million in a non‑discretionary sell‑to‑cover transaction executed under a Rule 10b5‑1 plan. The sale leaves Polovin with 138,140 shares and does not reflect a change in his view on the company. Tempus's shares surged ~75% recently after a Moderna‑Merck cancer vaccine trial validated sequencing technology tied to Tempus's pending Personalis deal, while the company reported 22% revenue growth to $382.5 million and its first GAAP profit last quarter, prompting debate whether the rally already prices in future trial readouts. » Altro su finance.yahoo.com